<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35963498</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0038</ISSN><JournalIssue CitedMedium="Internet"><Volume>843</Volume><PubDate><Year>2022</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Gene</Title><ISOAbbreviation>Gene</ISOAbbreviation></Journal><ArticleTitle>Characterisation of retrotransposon insertion polymorphisms in whole genome sequencing data from individuals with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>146799</StartPage><MedlinePgn>146799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2022.146799</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-1119(22)00618-7</ELocationID><Abstract><AbstractText>The genetics of an individual is a crucial factor in understanding the risk of developing the neurodegenerative disease amyotrophic lateral sclerosis (ALS). There is still a large proportion of the heritability of ALS, particularly in sporadic cases, to be understood. Among others, active transposable elements drive inter-individual variability, and in humans long interspersed element 1 (LINE1, L1), Alu and SINE-VNTR-Alu (SVA) retrotransposons are a source of polymorphic insertions in the population. We undertook a pilot study to characterise the landscape of non-reference retrotransposon insertion polymorphisms (non-ref RIPs) in 15 control and 15 ALS individuals' whole genomes from Project MinE, an international project to identify potential genetic causes of ALS. The combination of two bioinformatics tools (mobile element locator tool (MELT) and TEBreak) identified on average 1250 Alu, 232 L1 and 77 SVA non-ref RIPs per genome across the 30 analysed. Further PCR validation of individual polymorphic retrotransposon insertions showed a similar level of accuracy for MELT and TEBreak. Our preliminary study did not identify a specific RIP or a significant difference in the total number of non-ref RIPs in ALS compared to control genomes. The use of multiple bioinformatic tools improved the accuracy of non-ref RIP detection and our study highlights the potential importance of studying these elements further in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Abigail L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacoangeli</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London SE5 9RT, UK; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schumann</LastName><ForeName>Gerald G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen 63225, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio-Roldan</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genomic Medicine and Department of Oncology, GENYO, Centre for Genomics &amp; Oncology, PTS Granada, 18007, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Perez</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Genomic Medicine and Department of Oncology, GENYO, Centre for Genomics &amp; Oncology, PTS Granada, 18007, Spain; MRC-HGU Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Khleifat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London SE5 9RT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koks</LastName><ForeName>Sulev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Perron Institute for Neurological and Translational Science, Perth, Western Australia 6009, Australia; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Western Australia 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bubb</LastName><ForeName>Vivien J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London SE5 9RT, UK; Department of Neurology, King's College Hospital, London SE5 9RS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK. Electronic address: jquinn@liv.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>QUINN/APR15/843-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Gene</MedlineTA><NlmUniqueID>7706761</NlmUniqueID><ISSNLinking>0378-1119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018626">Retroelements</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020084" MajorTopicYN="N">Long Interspersed Nucleotide Elements</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018626" MajorTopicYN="N">Retroelements</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alu</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">LINE-1</Keyword><Keyword MajorTopicYN="N">Polymorphism</Keyword><Keyword MajorTopicYN="N">Retrotransposon</Keyword><Keyword MajorTopicYN="N">SVA</Keyword><Keyword MajorTopicYN="N">Whole genome sequencing</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>19</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35963498</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2022.146799</ArticleId><ArticleId IdType="pii">S0378-1119(22)00618-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>